Use of biologics for psoriasis in Central and Eastern European countries

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 11, 2015, Pages 2222-2230

  Rencz, F ^a,b   Kemeny L ^c   Gajdacsi J Z ^d   Owczarek, W ^e   Arenberger, P ^f   Tiplica, G S ^g   Stanimirovic, A ^h   Niewada, M ⁱ   Petrova, G ^j   Marinov, L T ^j   Pentek M ^a   Brodszky, V ^a   Gulacsi L ^a  

^a Institute of Data Analytics and Information Systems   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d National Health Insurance Fund   (Hungary)

^e MILITARY INSTITUTE OF MEDICINE   (Poland)

^f CHARLES UNIVERSITY   (Czech Republic)

^g CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h University of Applied Health Sciences   (Croatia)

ⁱ MEDICAL UNIVERSITY OF WARSAW   (Poland)

^j MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; ETANERCEPT; INFLIXIMAB; USTEKINUMAB;

ARTICLE; BIOLOGICAL THERAPY; BODY SURFACE; BUDGET; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DERMATOLOGY LIFE QUALITY INDEX; EASTERN EUROPE; HUMAN; MAINTENANCE THERAPY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; TREATMENT DURATION; BULGARIA; CROATIA; CZECH REPUBLIC; ECONOMICS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HUNGARY; INSURANCE; POLAND; ROMANIA; STATISTICS AND NUMERICAL DATA;

BIOLOGICAL PRODUCTS; BULGARIA; CROATIA; CZECH REPUBLIC; GUIDELINE ADHERENCE; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; HUNGARY; INSURANCE COVERAGE; INSURANCE, HEALTH; POLAND; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PSORIASIS; ROMANIA;

EID: 84945445313     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13222     Document Type: Article

References (39)

1. Pathirana D, Ormerod AD, Saiag P, et al,. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
2. European Medicines Agency. [WWW document]. URL http://www.ema.europa.eu/ema/ (last accessed: 08 November 2014).
3. de Korte J, Sprangers MA, Mombers FM, Bos JD,. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-147.
4. Heredi E, Rencz F, Balogh O, et al,. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ 2014; 15 (Suppl 1): S111-S119.
5. Rencz F, Hollo P, Karpati S, et al,. Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity. J Eur Acad Dermatol Venereol 2015; 29: 1398-1405.
6. Reich K, Segaert S, Van de Kerkhof P, et al,. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 2009; 219: 239-249.
7. Revicki D, Willian MK, Saurat JH, et al,. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-557.
8. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA,. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
9. Putrik P, Ramiro S, Kvien TK, et al,. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014; 73: 198-206.
10. Pentek M, Poor G, Wiland P, et al,. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ 2014; 15 (Suppl 1): S35-S43.
11. Rencz F, Péntek M, Bortlik M, et al,. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol 2015; 21: 1728-1737.
12. Eurostat Statistics Database. [WWW document] 2013. URL http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/search-database (last accessed: 10 August 2014).
13. World Bank Databank. [WWW document] 2012. URL http://databank.worldbank.org/data/home.aspx (last accessed: 10 August 2014).
14. Barisic-Drusko V, Palja n D, Kansky A, Vujasinovic S,. Prevalence of psoriasis in Croatia. Acta Derm Venereol Suppl (Stockh) 1989; 146: 178-179.
15. Del Toso-Depeder Z,. Prevalence of psoriasis in the Karlovac region. Lijec Vjesn 1993; 115: 21-27.
16. Popescu R, Popescu CM, Williams HC, Forsea D,. The prevalence of skin conditions in Romanian school children. Br J Dermatol 1999; 140: 891-896.
17. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM,. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.
18. Balogh O, Brodszky V, Gulacsi L, et al,. Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur J Health Econ 2014; 15 (Suppl 1): S101-S109.
19. Klimes J, Dolezal T,. Indirect costs of moderate to severe forms of psoriasis in Czech Republic: calculation based self reported questionnaire. Value Health 2010; 13: A468.
20. Petrikova A, Klimes J, Dolezal T, Marinov L, Petrova G,. Treatment of patients with moderate and severe psoriasis-cost-of-illness in the Czech Republic. Value Health 2011; 14: A305-A306.
21. Władysiuk M, Fedyna M, Bebrysz M, et al,. Indirect costs of rheumatoid arthritis, Crohn's disease and psoriasis in Poland. Health Technology Assessment International Conference 2014. [WWW document] June 2014: 60. URL http://www.htai2014.org/temp/20147448232/OR244.pdf (last accessed: 08 October 2014).
22. Rencz F, Brodszky V, Péntek M, et al,. Disease burden of psoriasis associated with psoriatic arthritis in Hungary. Orv Hetil 2014; 155: 1913-1921.
23. Arenberger P,. Organizace biologické lécby v CR. 1st conference of biological medicines 2010. [WWW document] November 12-13., 2010. URL http://www.prolekare.cz/odborny-event/organizace-biologicke-lecby-v-cr-11 (last accessed: 10 August 2014).
24. Országos Egészségbiztosítási Pénztár, Orvosszakértoi és Szakmai Ellenorzési Foosztály. A plakkos psoriasis diagnosztikájának és kezelésének finanszírozási protokollja (eljárásrend). [WWW document] 2013.06.26. URL http://site.oep.hu/steam/downloads/finprot-20131115/hatalyos/0626-a-plakkos-psoriasis-diagnosztikajanak-es-kezelesenek-finanszirozasi-protokollja.pdf (last accessed: 10 August 2014).
25. Kadurina M, Vassileva S, Gospodinov D, et al,. Guidelines for the Treatment of Psoriasis by Biological Products of Bulgarian Dermatological Society. [WWW document] 2013. URL http://www.bg-derm.org/wp-content/uploads/2013/06/02-Guideline-for-biologicals.pdf (last accessed: 10 August 2014).
26. Mrowietz U, Kragballe K, Reich K, et al,. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
27. Ormerod AD, Augustin M, Baker C, et al,. Challenges for synthesising data in a network of registries for systemic psoriasis therapies. Dermatology 2012; 224: 236-243.
28. Brodszky V, Baji P, Balogh O, Pentek M,. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014; 15 (Suppl 1): S65-S71.
29. Laki J, Monok G, Palosi M, Gajdacsi JZ,. Economical aspect of biological therapy in inflammatory conditions in Hungary. Expert Opin Biol Ther 2013; 13: 327-337.
30. Gulacsi L, Rencz F, Pentek M, et al,. Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. Eur J Health Econ 2014; 15 (Suppl 1): S27-S34.
31. Gulacsi L, Pentek M,. HTA in Central and Eastern European countries; the 2001: a space odyssey and efficiency gain. Eur J Health Econ 2014; 15: 675-680.
32. Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG,. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 685-705.
33. Zhang W, Islam N, Ma C, Anis AH,. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics 2015; 33: 327-340.
34. Agencja Oceny Technologii Medycznych. Wydzial do Spraw Systemõw Ochrony Zdrowia. Wniosek o objecie refundacja leku Stelara (ustekinumab), 45 mg, w ramach programu lekowego: Leczenie ciezkiej postaci luszczycy pospolitej z zastosowaniem ustekinumabu. Analiza weryfikacyjna 2012. [WWW document]. URL http://www.aotm.gov.pl/bip/assets/files/zlecenia-mz/2012/044/AWA/044-AWA-DS-433-05-Stelara-luszczyca-2012.08.13.pdf (last accessed: 12 December 2014).
35. Gulacsi L, Rotar AM, Niewada M, et al,. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ 2014; 15 (Suppl 1): S13-S25.
36. Gniadecki R, Robertson D, Molta CT, et al,. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 2012; 26: 1436-1443.
37. Luger TA, Barker J, Lambert J, et al,. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 896-904.
38. Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA,. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat 2007; 18: 25-31.
39. European Central Bank. Euro foreign exchange reference rates. [WWW document]. URL https://www.ecb.europa.eu/stats/exchange/eurofxref/html/index.en.html (last accessed: 17 April 2015).